Press release
Monopar Announces Promising MNPR-202 Data from Ongoing National University of Singapore Collaboration
WILMETTE, Ill, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing
About this update from Monopar Therapeutics Inc.
[{"type":"text","content":"WILMETTE, Ill, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today released promising data with MNPR-202 from its ongoing collaboration with the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS). The data are displayed in the poster that NUS and Monopar will be presenting this Sunday at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition (ASH 2022). Monopar has made the poster available on its website at the following link: https://www.monopartx.com/pipeline/mnpr-202. MNPR-202 is a promising DNA Damaging Response (DDR) drug candidate, and analog of doxorubicin. It has the same potentially non-cardiotoxic backbone as camsirubicin, Monopar’s clinical stage drug candidate that has shown a favorable heart toxicity profile to-date across three trials, but MNPR-202 is modified at additional sites with the intention of evading certain tumors’ resistance mechanisms to doxorubicin. Prior exploratory preclinical studies in solid tumors have shown MNPR-202 to have a similar cytotoxic potency to doxorubicin while retaining that potency even in doxorubicin-resistant cancers. The present preclinical work by Dr. Anand Jeyasekharan, MD PhD, of CSI Singapore, which was highlighted by the Gates Cambridge in a recent article: https://www.gatescambridge.org/about/news/scholars-join-forces-on-anti-cancer-drug/, corroborates MNPR-202’s similar cytotoxic potency to doxorubicin even in blood cancers, while expanding the research in several exciting new directions, including a comparison to doxorubicin on DNA damage response, immune activation, apoptosis, gene expression, and synergy with other cancer compounds for combination usage. Preclinical Results To-Date Data from blood cancer preclinical studies to date show that MNPR-202: - has a similar cytotoxic potency to doxorubicin - generates increased DNA damage compared to doxorubicin - has a unique immune activation profile versus doxorubicin - demonstrates increased apoptosis compared to doxorubicin - causes a distinct set of genes to be upregulated and downregulated versus doxorubicin; and - may be superior to doxorubicin in certain comb...